Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK MenACWY-TT Vaccine Formulations vs Mencevax in Adolescents
NCT00196963Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2005
- Primary completion
- Jul 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal disease (5 arms), sponsored by GSK. Primary endpoints: Percentage of subjects with >= 4-fold increase in SBA-MenA titre at 1 month, Percentage of subjects with >= 4-fold increase in SBA-MenC titre at 1 month and 2 more. Started Mar 2005; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00196963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196963.